By Stephen Prescott, M.D. When Novartis announced earlier this month that the U.S. Food and Drug Administration had approved the company’s new drug to treat sickle cell anemia, the press release didn’t mention Oklahoma. But it should have. That drug, known as Adakveo, is as Oklahoman as redbuds and scissor-tailed flycatchers. Indeed, but for workRead more
News
